MAPT and Alzheimer disease: In the present study, we observed that core AD biomarkers were lower (Aβ42) or higher (T-tau, P-tau181) in SCD compared to controls, although maintaining a large overlap between the two groups, while N-224 could not distinguish between controls and SCD.